ASCO 2025 | Does lifileucel have a role in the first-line setting for melanoma?
Theresa Medina, MD, University of Colorado Comprehensive Cancer Center, Aurora, CO, discusses the emerging potential of lifileucel, a tumor-infiltrating lymphocyte (TIL) cell therapy, in earlier lines of melanoma treatment. Lifileucel was assessed in the ongoing Phase III TILVANCE-301 trial (NCT05727904) as a first-line treatment compared to checkpoint inhibitors, and displayed a favorable response profile. This interview took place at the 2025 American Society of Clinical Oncology (ASCO) meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Since we see this long-term durability that’s relatively tolerable for patients, we do see that the majority of the toxicities from this therapy resolve pretty rapidly after initial treatment. So, we are looking at this. I’m also an investigator on the Phase III first-line study, which is randomized, looking at lifileucel for first-line treatments in patients with advanced or metastatic melanoma compared to a control arm with an immune checkpoint inhibitor...
Since we see this long-term durability that’s relatively tolerable for patients, we do see that the majority of the toxicities from this therapy resolve pretty rapidly after initial treatment. So, we are looking at this. I’m also an investigator on the Phase III first-line study, which is randomized, looking at lifileucel for first-line treatments in patients with advanced or metastatic melanoma compared to a control arm with an immune checkpoint inhibitor.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
